KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$7.37 USD
+0.29 (4.10%)
Updated Jul 24, 2024 02:59 PM ET
After-Market: $7.13 -0.24 (-3.26%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for KALA BIO, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 4 | 11 | 6 | 6 |
Cost Of Goods | 0 | 3 | 4 | 3 | 2 |
Gross Profit | 0 | 1 | 7 | 3 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 40 | 83 | 137 | 99 | 92 |
Income After Depreciation & Amortization | -40 | -82 | -130 | -96 | -88 |
Non-Operating Income | 3 | 44 | -4 | 0 | 2 |
Interest Expense | 6 | 7 | 8 | 9 | 8 |
Pretax Income | -42 | -45 | -143 | -104 | -94 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -42 | -45 | -143 | -104 | -94 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -42 | -45 | -143 | -104 | -94 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -38 | -80 | -128 | -94 | -86 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -40 | -82 | -130 | -96 | -88 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.43 | 1.52 | 1.30 | 1.05 | 0.68 |
Diluted EPS Before Non-Recurring Items | -17.35 | -29.48 | -109.50 | -99.50 | -138.00 |
Diluted Net EPS (GAAP) | -17.35 | -29.48 | -109.50 | -99.50 | -138.00 |
Fiscal Year end for KALA BIO, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 11.93 | 9.62 | 8.76 | 9.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -11.93 | -9.62 | -8.76 | -9.60 |
Non-Operating Income | NA | 1.58 | 2.46 | 1.52 | 0.60 |
Interest Expense | NA | 1.46 | 1.47 | 1.46 | 1.41 |
Pretax Income | NA | -11.81 | -8.63 | -8.70 | -10.41 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.81 | -8.63 | -8.70 | -10.41 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -11.81 | -8.63 | -8.70 | -10.41 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 2.81 | 2.71 | 2.55 | 2.39 |
Diluted EPS Before Non-Recurring Items | NA | -4.20 | -3.18 | -3.41 | -4.36 |
Diluted Net EPS (GAAP) | NA | -4.20 | -2.59 | -3.41 | -4.36 |